Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide plus VTD versus VTD for newly diagnosed multiple myeloma
ChiCTR2000031318Phase 4Recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of arsenic trioxide, bortezomib, thalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Huadong Hospital, Fudan University. Primary endpoints: M protein and progression-free survival. Started Mar 2020; status: recruiting.
02
Drugs
arsenic trioxidebortezomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2000031318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031318.